3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
48
Nivolumab
22
Cyclophosphamide
10
Carboplatin
10
spartalizumab
8
atezolizumab
7
Gemcitabine
7
130-nm albumin-bound paclitaxel
7
fludarabine
6
Cisplatin
6
Ipilimumab
5
durvalumab
4
budigalimab
4
avelumab
4
Pemetrexed
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Irinotecan
4
Interleukin-2
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
Bevacizumab
4
cemiplimab
3
cabozantinib
3
aldesleukin
3
Standard of Care
3
Specimen Handling
3
Oxaliplatin
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Clinical Trials, Phase II as Topic
×
Thoracic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled